Loading...



Shopping cart processing ...
0
Your cart0
Products 0
Price $0.00
Bestsellers Pill categories
Customer Support 24/7
usa canada USA
uk UK
au AU
Live Chat 24/7
Menu
Customer Support 24/7
USA/Canada Toll Free USA
UK UK
AUS AU
Customer Support 24/7
usacanada USA
uk UK
au AU
We accept
  • Visa
  • MasterCard
  • Amex
  • JCB
Currency
USD
Your cart: $0.00 (0 items)
Checkout

Categories list

Choosing us you get:

  • Reliable supplier
  • Low Internet prices
  • Free bonus pills
  • Discount on all future orders
  • Discreet package
  • SSL secure orders
Worldwide Shipping!

Testimonials:

  • Craig Wolfe Craig Wolfe Vidalia, GA, USA
    Hi every one. I am 61 and I buy Generic Viagra within 5 years. In my age it is quite hesitating to come to pharmacy and buy Viagra openly, but thanks to your online-store I always get quality product in time with 10% discount.
More info »

Rhinocort

Rhinocort
Rhinocort (Budesonide) works by decreasing irritation and inflammation in the lungs; it widens the airways in the lungs, which helps you breathe more easily.

Brand: Budesonide

Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: April 2024
View product image
Package Price Per pill Save Order
Rhinocort 200 mcg
6 inhalers - 200 mcg
+ 12 free Viagra 100 mg, 7% discount for future orders
$312.75 $52.13 $66.15 Add to cart
3 inhalers - 200 mcg
+ 4 free Viagra 100 mg, 3% discount for future orders
$165.65 $55.22 $23.80 Add to cart
1 inhalers - 200 mcg $63.15 $63.15 No Add to cart
Rhinocort 100 mcg
6 inhalers - 100 mcg
+ 4 free Viagra 100 mg, 3% discount for future orders
$199.95 $33.33 $51.75 Add to cart
3 inhalers - 100 mcg
+ 4 free Viagra 100 mg, 3% discount for future orders
$104.93 $34.98 $20.92 Add to cart
1 inhalers - 100 mcg $41.95 $41.95 No Add to cart

Product description

Drug Title

Rhinocort (Budesonide)

Pharmacological action

GCS. When inhaled, it has anti-inflammatory, anti-allergic and anti-exudative effect, which leads to a reduction of bronchial obstruction. The mechanism of action is to inhibit the release of mediators of inflammation and allergy, as well as to reduce the reactivity of the airways to their action. During treatment, respiratory function improves, the severity and frequency of dyspnea, attacks of suffocation, coughing decreases significantly. The maximum clinical effect develops after 1-2 weeks of therapy.


The exact mechanism of action of budesonide in treatment of ulcerative colitis is not fully established. Rhinocort (Budesonide) inhibits many inflammatory processes, including cytokine production, activation of inflammatory infiltrate cells and expression of adhesive molecules on endothelial and epithelial cells. At doses that are clinically consistent with prednisolone, Rhinocort (Budesonide) causes significantly less suppression of the hypothalamic-pituitary-adrenal axis and has less effect on inflammatory markers.


Data from clinical pharmacological and pharmacokinetic studies indicate that the mechanism of action of budesonide when taken orally is based on local action in the gut.


Pharmacokinetics

When administered by inhalation, 30-35% of the dose penetrates into the bronchioles. Bioavailability upon entry into the lungs is about 73%. 25-30% enters the gastrointestinal tract. Bioavailability by oral route of administration is 10.7%. Cmax of budesonide in plasma is reached after 1.5-2 hours. Budesonide is rapidly excreted from the body. T1/2 when administered by inhalation is 2-3 hours. Plasma clearance is 55-85 l/h.


After oral administration in special dosage form, approximately 90% of budesonide is metabolized during "first passage" through the liver and only about 10% is systemic availability. Rhinocort (Budesonide) has a significant Vd (about 3 L/kg). Binding to plasma proteins averages 85-90%. Rhinocort (Budesonide) undergoes extensive biotransformation in the liver to form metabolites with low glucocorticoid activity. Glucocorticoid activity of the main metabolites (6β-hydroxybudesonide and 16α-hydroxyprednisolone) does not exceed 1% of activity of budesonide itself. Budesonide metabolism is mainly mediated by CYP3A isoenzymes. The excretion rate of budesonide is limited by the degree of absorption. Rhinocort (Budesonide) is characterized by high systemic clearance (about 1.2 L/min).

Contraindications for use

Hypersensitivity to budesonide.


For inhaled use: children under 6 months of age; children over 6 months of age - depending on the dosage form used. With caution: tuberculosis, fungal, bacterial and viral respiratory infections, liver cirrhosis, glaucoma, hypothyroidism, osteoporosis.


As for oral and rectal administration: liver cirrhosis; children under 18 years old. With caution: tuberculosis, arterial hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma, cataracts, conjugate family history of diabetes or glaucoma; pregnancy.


Administration during pregnancy and lactation

Application during pregnancy is possible in case when the expected benefits to a mother outweigh the potential risk to a fetus.


If it is necessary to use during lactation, breastfeeding should be discontinued.


Administration in patients with liver dysfunction

Oral administration in patients with liver cirrhosis is contraindicated.


Caution should be exercised when using in patients with significant liver dysfunction.


Administration in patients with impaired renal function

Use with caution in patients with diagnosed renal dysfunction.

Administration in children

Inhaled is contraindicated for use in children under 6 years of age.


Oral administration is contraindicated in children and teenagers under 18 years of age.


Administration in elderly patients

Caution should be exercised when prescribing in elderly patients in order to prevent deterioration of comorbidities.

Indications for the active substance BUDESONID

For inhaled use: treatment of bronchial asthma (as basic therapy; in case of ineffectiveness of beta2-adrenomimetics; for dose reduction of oral GCS); treatment of COPD; stenotic laryngotracheitis (false croup).


For intranasal use: prevention and treatment of seasonal and year-round allergic rhinitis; non-allergic rhinitis; nasal polyps.


Oral administration: induction of remission in patients with exacerbation of mild to moderate forms of Crohn's disease with lesions of the ileum and/or ascending colon; induction of remission in patients with active collagenous colitis.


For rectal use: exacerbation of distal forms of ulcerative colitis (with lesions of the rectum and sigmoid colon).


Dosage regimen

It is administered by inhalation, intranasally, internally, rectally.


It is established individually, depending on indications, age, dosage form.